Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Nvs crawled date : 2022 - 03 - 25 save search
Worldwide Malaria Diagnostics Industry to 2026 - Featuring Access Bio, Novartis and Olympus Among Others
Published: 2022-03-25 (Crawled : 21:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
NINOF | $10.2 -14.1% 100
|
Consumer Durables
| Email alert
Add to watchlist
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
| Email alert
Add to watchlist
DHR | $235.51 -0.36% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
NINOY | $9.56 -3.3% 1.3K
|
Manufacturing
| Email alert
Add to watchlist
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
| Email alert
Add to watchlist
novartis diagnostics diagnostic malaria
Drugs for Immunotherapy Global Market Report 2022
Published: 2022-03-25 (Crawled : 18:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -6.55%
H: 7.81%
C: 7.56%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.28%
H: 1.09%
C: 0.18%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.58%
H: 1.16%
C: 0.23%
immunotherapy report market drug
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
Published: 2022-03-25 (Crawled : 14:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.33%
H: 0.29%
C: 0.01%
jakavi treatment disease positive chmp
Cellular Immunotherapy Global Market Report 2022
Published: 2022-03-25 (Crawled : 14:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
immunotherapy report market
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
kymriah novartis europe car-t positive therapy chmp t-cell
Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
jakavi novartis disease positive chmp
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.